T 2552/22 (Anti-LAG-3 antibodies) of 13.05.2025
- European Case Law Identifier
- ECLI:EP:BA:2025:T255222.20250513
- Date of decision
- 13 May 2025
- Case number
- T 2552/22
- Online on
- 21 August 2025
- Petition for review of
- -
- Application number
- 15156647.8
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Human antibodies that bind lymphocyte activation gene-3 (LAG-3) and uses thereof
- Applicant name
- E. R. Squibb & Sons, L.L.C.
- Opponent name
- Regeneron Pharmaceuticals, Inc.
- Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 56Rules of procedure of the Boards of Appeal 2020 Art 012(4)Rules of procedure of the Boards of Appeal 2020 Art 012(6)
- Keywords
- Inventive step - obvious alternative
Amendment to case - amendment within meaning of Art. 12(4) RPBA 2020 (yes)
Amendment to case - admitted (yes) - Catchword
- -
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The patent is revoked.